Sun Pharma to Acquire Organon for $11.8B

Sun Pharma (India) agreed to buy US‑listed Organon in an all‑cash deal valued at about $11.75 billion ($14 per share).
The acquisition adds over 70 women’s health and general medicines products and presence in more than 140 markets to Sun Pharma’s portfolio.
Combined pro‑forma revenue will be roughly $12.4 billion, placing Sun Pharma among the top 25 global pharma firms and top‑three in women’s health.
Deal to be financed by cash and committed bank loans, pending regulatory and shareholder approvals, with expected closing in early 2027.